| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 1.837 | 3.327 | 1.977 | 1.907 | 2.264 | 1.850 | 1.284 | 1.102 | 965 | 5.550 |
| Total Income - EUR | 1.837 | 3.327 | 1.977 | 1.907 | 2.264 | 1.850 | 1.284 | 1.102 | 965 | 5.560 |
| Total Expenses - EUR | 46 | 355 | 732 | -415 | 464 | 657 | 2.147 | 1.200 | -86 | 4.197 |
| Gross Profit/Loss - EUR | 1.791 | 2.973 | 1.245 | 2.322 | 1.800 | 1.192 | -863 | -98 | 1.051 | 1.363 |
| Net Profit/Loss - EUR | 1.736 | 2.873 | 1.186 | 2.265 | 1.737 | 1.137 | -902 | -98 | 985 | 1.173 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Neuromed Bontu Srl
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 12 | 51 | 3 | 711 | 496 | 1.340 | 443 | 335 | 707 | 7.414 |
| Inventories | 0 | 8 | 0 | 710 | 388 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 539 | 159 | 122 | 0 | 128 |
| Cash | 12 | 43 | 3 | 1 | 108 | 801 | 284 | 214 | 707 | 7.286 |
| Shareholders Funds | -8.199 | -5.188 | -3.907 | -1.567 | 200 | 1.332 | 434 | 335 | 1.318 | 7.731 |
| Social Capital | 620 | 609 | 598 | 586 | 575 | 563 | 564 | 563 | 559 | 2.783 |
| Debts | 8.211 | 5.239 | 3.910 | 2.278 | 296 | 7 | 9 | 0 | -611 | -317 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 1 | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Neuromed Bontu Srl